To further confirm the ability of FGFR signaling to drive resistance to ErbB inhibition we analyzed the CCLE database by comparing the documented IC50 values for Lapatinib and the corresponding expression levels of the FGFR1 in 27 analyzed breast cancer cell lines (Supplementary Figure S3A). The gene discussed is FGFR1; the disease is breast cancer.